Amanullah Khan
Hematology & Oncology · McKinney, TXNPI 1114922531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $572 and has fallen 83.6% since, to $94 in 2023. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 102 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$221
- Tactile Systems Technology Inc$133
- Pfizer$112
- Bristol Myers Squibb$111
- Merck$105
- Astellas Pharma US Inc$98
- plus $850 from 29 others
What the payments were for
- Food & beverage$1,60498%
- Education$262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 21 | $221 |
| Tactile Systems Technology Inc | 10 | $133 |
| Pfizer | 7 | $112 |
| Bristol Myers Squibb | 5 | $111 |
| Merck | 6 | $105 |
| Astellas Pharma US Inc | 5 | $98 |
| Puma Biotechnology, Inc. | 5 | $82 |
| Incyte Corporation | 3 | $63 |
| Sanofi | 2 | $47 |
| Medtronic(2 entities) | 3 | $45 |
| Genentech USA, Inc. | 3 | $43 |
| Bayer | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Gilead | 2 | $37 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Epizyme, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $28 |
| Novartis | 2 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Lilly USA, LLC | 2 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Dova Pharmaceuticals | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $18 |
| Mylan Institutional Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
How this compares
$1,630 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in McKinney
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.